The Vanguard Group 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-31 10:09 am Sale | 2024-12-31 | 13G | Travere Therapeutics, Inc. TVTX | The Vanguard Group | 6,742,165 7.750% | -159,985 (-2.32%) | Filing |
| 2024-11-12 5:56 pm Unchanged | 2024-09-30 | 13G | Travere Therapeutics, Inc. TVTX | The Vanguard Group | 6,902,150 9.020% | 0 (Unchanged) | Filing |
| 2024-11-04 1:55 pm Purchase | 2024-09-30 | 13G | Travere Therapeutics, Inc. TVTX | The Vanguard Group | 6,902,150 9.020% | 1,387,007 (+25.15%) | Filing |
| 2024-02-13 5:16 pm Purchase | 2023-12-29 | 13G | Travere Therapeutics, Inc. TVTX | The Vanguard Group | 5,515,143 7.340% | 1,999,697 (+56.88%) | Filing |
| 2023-02-09 11:35 am Sale | 2022-12-30 | 13G | Travere Therapeutics, Inc. TVTX | The Vanguard Group | 3,515,446 5.480% | -365,427 (-9.42%) | Filing |
| 2022-02-10 08:42 am Purchase | 2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX | The Vanguard Group | 3,880,873 6.340% | 476,430 (+13.99%) | Filing |
| 2021-02-10 11:57 am Purchase | 2020-12-31 | 13G | Travere Therapeutics, Inc. TVTX | The Vanguard Group | 3,404,443 6.670% | 3,404,443 (New Position) | Filing |